PURPOSE: The purpose of this study was to investigate the prognostic value of time to relapse in 188 adult patients with intermediate- or high-grade non-Hodgkin's lymphoma (NHL) included on the Parma trial at the time of their first relapse. PATIENTS AND METHODS: The median follow-up of these patients is 102 months after registration onto the Parma study. Time to relapse was calculated from initial diagnosis, and a cutoff of 12 months was used to separate 77 patients defined as early relapse from 111 patients defined as late relapse. RESULTS: Patients with early and late relapses had significantly different overall response rates to salvage therapy with two courses of dexamethasone, high-dose cytarabine, and cisplatin (DHAP; 40% v 69%; P=.00007) and different 8-year survival rates (13% v 29%; P=.00001). Features at relapse with a negative prognostic value in univariate analysis were higher than normal lactic dehydrogenase (LDH) levels, tumor size greater than 5 cm, Ann Arbor stages III to IV, and Karnofsky score less than 80%. Therefore, multivariate analyses were performed. Time to relapse (P=.001) and LDH levels at relapse (P=.003) had independent prognostic value, whereas tumor size did not reach statistical significance in the logistic model that predicted overall response after two courses of DHAP. The study of prognostic factors for overall survival (OS) and progression-free survival (PFS) confirmed the prognostic value of time to relapse (P < .0001 for OS and P=.005 for PFS) independent of response or treatment after two courses of DHAP. CONCLUSION:Time to relapse may be used to stratify patients at time of first relapse of intermediate to high-grade non-Hodgkin's lymphoma.
RCT Entities:
PURPOSE: The purpose of this study was to investigate the prognostic value of time to relapse in 188 adult patients with intermediate- or high-grade non-Hodgkin's lymphoma (NHL) included on the Parma trial at the time of their first relapse. PATIENTS AND METHODS: The median follow-up of these patients is 102 months after registration onto the Parma study. Time to relapse was calculated from initial diagnosis, and a cutoff of 12 months was used to separate 77 patients defined as early relapse from 111 patients defined as late relapse. RESULTS:Patients with early and late relapses had significantly different overall response rates to salvage therapy with two courses of dexamethasone, high-dose cytarabine, and cisplatin (DHAP; 40% v 69%; P=.00007) and different 8-year survival rates (13% v 29%; P=.00001). Features at relapse with a negative prognostic value in univariate analysis were higher than normal lactic dehydrogenase (LDH) levels, tumor size greater than 5 cm, Ann Arbor stages III to IV, and Karnofsky score less than 80%. Therefore, multivariate analyses were performed. Time to relapse (P=.001) and LDH levels at relapse (P=.003) had independent prognostic value, whereas tumor size did not reach statistical significance in the logistic model that predicted overall response after two courses of DHAP. The study of prognostic factors for overall survival (OS) and progression-free survival (PFS) confirmed the prognostic value of time to relapse (P < .0001 for OS and P=.005 for PFS) independent of response or treatment after two courses of DHAP. CONCLUSION: Time to relapse may be used to stratify patients at time of first relapse of intermediate to high-grade non-Hodgkin's lymphoma.
Authors: Yago Nieto; Peter Thall; Ben Valdez; Borje Andersson; Uday Popat; Paolo Anderlini; Elizabeth J Shpall; Roland Bassett; Amin Alousi; Chitra Hosing; Partow Kebriaei; Muzaffar Qazilbash; Erin Frazier; Alison Gulbis; Christina Chancoco; Qaiser Bashir; Stefan Ciurea; Issa Khouri; Simrit Parmar; Nina Shah; Laura Worth; Gabriela Rondon; Richard Champlin; Roy B Jones Journal: Biol Blood Marrow Transplant Date: 2012-05-27 Impact factor: 5.742
Authors: Ho-Young Yhim; Yael Eshet; Ur Metser; Chae-Hong Lim; Katherine Lajkosz; Keren Isaev; Matthew Cooper; Anca Prica; Vishal Kukreti; Sita Bhella; Noémie Lang; Kyung-Han Lee; Wei Xu; David Hodgson; Richard Tsang; Sang Eun Yoon; Seok Jin Kim; Won Seog Kim; Michael Crump; John Kuruvilla; Robert Kridel Journal: Blood Adv Date: 2020-11-24
Authors: Yago Nieto; Benigno C Valdez; Peter F Thall; Sairah Ahmed; Roy B Jones; Chitra Hosing; Uday Popat; Elizabeth J Shpall; Muzaffar Qazilbash; Alison Gulbis; Paolo Anderlini; Amin Alousi; Nina Shah; Qaiser Bashir; Yan Liu; Yasuhiro Oki; Frederick Hagemeister; Michelle Fanale; Bouthaina Dabaja; Chelsea Pinnix; Richard Champlin; Borje S Andersson Journal: Biol Blood Marrow Transplant Date: 2015-06-11 Impact factor: 5.742
Authors: Alex F Herrera; Matthew Mei; Lawrence Low; Haesook T Kim; Gabriel K Griffin; Joo Y Song; Reid W Merryman; Victoria Bedell; Christine Pak; Heather Sun; Tanya Paris; Tracey Stiller; Jennifer R Brown; Lihua E Budde; Wing C Chan; Robert Chen; Matthew S Davids; Arnold S Freedman; David C Fisher; Eric D Jacobsen; Caron A Jacobson; Ann S LaCasce; Joyce Murata-Collins; Auayporn P Nademanee; Joycelynne M Palmer; German A Pihan; Raju Pillai; Leslie Popplewell; Tanya Siddiqi; Aliyah R Sohani; Jasmine Zain; Steven T Rosen; Larry W Kwak; David M Weinstock; Stephen J Forman; Dennis D Weisenburger; Young Kim; Scott J Rodig; Amrita Krishnan; Philippe Armand Journal: J Clin Oncol Date: 2016-10-24 Impact factor: 44.544
Authors: M Koenigsmann; J Casper; C Kahl; N Basara; H G Sayer; G Behre; S Theurich; M Christopeit; M Mohren; A Reichle; B Metzner; A Ganser; M Stadler; L Uharek; L Balleisen; A Hinke; R Hinke; D Niederwieser Journal: Bone Marrow Transplant Date: 2013-12-23 Impact factor: 5.483
Authors: Yago Nieto; Benigno C Valdez; Peter F Thall; Roy B Jones; Wei Wei; Alan Myers; Chitra Hosing; Sairah Ahmed; Uday Popat; Elizabeth J Shpall; Muzaffar Qazilbash; Alison Gulbis; Paolo Anderlini; Nina Shah; Qaiser Bashir; Amin Alousi; Yasuhiro Oki; Michelle Fanale; Bouthaina Dabaja; Chelsea Pinnix; Richard Champlin; Borje S Andersson Journal: Cancer Date: 2016-05-20 Impact factor: 6.860
Authors: Mehdi Hamadani; Parameswaran N Hari; Ying Zhang; Jeanette Carreras; Görgün Akpek; Mahmoud D Aljurf; Ernesto Ayala; Veronika Bachanova; Andy I Chen; Yi-Bin Chen; Luciano J Costa; Timothy S Fenske; César O Freytes; Siddhartha Ganguly; Mark S Hertzberg; Leona A Holmberg; David J Inwards; Rammurti T Kamble; Edward J Kanfer; Hillard M Lazarus; David I Marks; Taiga Nishihori; Richard Olsson; Nishitha M Reddy; David A Rizzieri; Bipin N Savani; Melhem Solh; Julie M Vose; Baldeep Wirk; David G Maloney; Sonali M Smith; Silvia Montoto; Wael Saber; Onder Alpdogan; Amanda Cashen; Christopher Dandoy; Robert Finke; Robert Gale; John Gibson; Jack W Hsu; Nalini Janakiraman; Mary J Laughlin; Michael Lill; Mitchell S Cairo; Reinhold Munker; Phil A Rowlings; Harry C Schouten; Thomas C Shea; Patrick J Stiff; Edmund K Waller Journal: Biol Blood Marrow Transplant Date: 2014-07-05 Impact factor: 5.742
Authors: Ulrich J M Mey; Vandana Jha; John W Strehl; Marcus Gorschlueter; Christian Rabe; Eckfried Hoebert; Henning Popp; Ingo G H Schmidt-Wolf Journal: Ger Med Sci Date: 2007-06-19